Skip to main content

Table 3 History of IgRT

From: Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

 

N = 116

  

Age at start of IgRT (years)

115a

33.34 ± 20.17

[0–79.7; 33.6]

Duration of IgRT (years)

115a

8.5 ± 8.4

[0.2–38.5; 5.6]

History of at least one switch from IVIg to SCIg

49

42.2 %

 

History of at least one switch from SCIg to IVIg

14

12.1 %

 

Route of IgRT at enrollment

   

• IVIg at hospital

46

39.7 %

 

• IVIg at home

13

11.2 %

 

• SCIg at home

57

49.1 %)

 

Switch from IVIg to SCIg after enrollment

11

9.5 %

 

Switch from SCIg to IVIg after enrollment

2

1.7 %

 

Switch from hospital-based to home-based IgRT

12

10.3 %

 

Switch from home-based to hospital-based IgRT

2

1.7 %

 
  1. amissing data for one patient